The drug was approved to treat patients who have already received chemotherapy under an accelerated approval process after a ...

AstraZeneca AZN is one of the leading drugmakers in the oncology space. Oncology sales (comprising around 41% of ...

Datroway is used to treat an advanced form of non-small cell lung cancer in adults who had received prior treatment.

FDA grants accelerated approval to AstraZeneca's Datroway for EGFR-mutant NSCLC after prior therapies, with a 45% response rate and a $45 million milestone due.

The US Food and Drug Administration (FDA) has approved AstraZeneca and Daiichi Sankyo's Datroway (Datopotamab deruxtecan) for adults with locally advanced or metastatic epidermal growth factor ...

Like many other major pharmaceutical companies, AstraZeneca is facing a series of patent cliffs for key treatments in its ...

AstraZeneca (AZ) and Daiichi Sankyo’s Datroway (datopotamab deruxtecan) has been granted accelerated approval by the US Food and Drug Administration (FDA) to treat a subset of non-small cell lung ...

AstraZeneca has begun a new agreement with Daiichi Sankyo to develop and market an antibody to treat cancer, worth up to $6 billion. The deal covers DS-1062, Daiichi Sankyo’s proprietary ...

AstraZeneca chief executive Pascal Soriot is considering moving the company's stock exchange listing from the UK to the US – ...

AstraZeneca and Daiichi Sankyo's Datroway drug has been approved in the U.S. to treat adult patients with non-small cell lung cancer. British pharmaceutical company AstraZeneca said Tuesday that ...

AstraZeneca and Daiichi Sankyo’s Datroway drug has been approved in the U.S. to treat adult patients with non-small cell lung cancer. British pharmaceutical company AstraZeneca said Tuesday that ...